A novel approach to cyclin-dependent kinase 5/p25 inhibitors: A potential treatment for Alzheimer's disease

Bioorg Med Chem. 2007 Oct 1;15(19):6397-406. doi: 10.1016/j.bmc.2007.06.053. Epub 2007 Jul 4.

Abstract

Based on the earlier results of our in-house database and compound library, a series of novel clubbed thienyl triazoles was designed which may emerge as potential cdk5/p25 inhibitors, for the treatment of Alzheimer's disease. A benign synthesis was planned so as to take an advantage of MAOS (Microwave Assisted Organic Synthesis) method. Evaluation of the SAR of this series has allowed the identification of compounds 4, 5, 7 and 8 from series I while 13, 14, 16 and 17 from series II as significant cdk5/p25 inhibitors and thus have potential as possible treatments for Alzheimer's disease.

MeSH terms

  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / pathology
  • Brain / drug effects*
  • Brain / metabolism
  • Cyclin-Dependent Kinase 5 / antagonists & inhibitors*
  • Enzyme Inhibitors / chemical synthesis
  • Enzyme Inhibitors / pharmacology*
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Microwaves
  • Nerve Tissue Proteins / antagonists & inhibitors*
  • Structure-Activity Relationship
  • Thiazoles / chemical synthesis
  • Thiazoles / pharmacology*
  • Ticrynafen / chemistry*

Substances

  • Enzyme Inhibitors
  • Nerve Tissue Proteins
  • TPPP protein, human
  • Thiazoles
  • Cyclin-Dependent Kinase 5
  • Ticrynafen